Inventiva ADR(IVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.37 | Insider Own | 7.56% | Shs Outstand | 239.1M | Perf Week | 4.64% |
| Market Cap | 0.92B | Forward P/E | - | EPS next Y | 0.85% | Insider Trans | - | Shs Float | 221.0M | Perf Month | 7.58% |
| Enterprise Value | 0.80B | PEG | - | EPS next Q | -0.16 | Inst Own | 28.92% | Short Float | 3.69% | Perf Quarter | -15.08% |
| Income | -0.29B | P/S | 15262.55 | EPS this Y | 67.73% | Inst Trans | 15.79% | Short Ratio | 4.26 | Perf Half Y | -27.32% |
| Sales | 0.00B | P/B | 13.42 | EPS next 5Y | 48.11% | ROA | -116.32% | Short Interest | 8.15M | Perf YTD | -17.63% |
| Book/sh | 0.29 | P/C | 4.82 | EPS past 3/5Y | -15.85% -13.59% | ROE | -1022.99% | 52W High | -47.46% ($7.29) | Perf Year | -10.93% |
| Cash/sh | 0.79 | P/FCF | - | Sales past 3/5Y | -26.61% 64.18% | ROIC | -224.94% | 52W Low | 35.82% ($2.82) | Perf 3Y | 1.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.37% | Gross Margin | -5232.81% | Volatility(W/M) | 6.35% 7.07% | Perf 5Y | -74.64% |
| Dividend TTM | - | EV/Sales | 13367.22 | Sales Y/Y TTM | -99.61% | Oper. Margin | -307068.32% | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | EPS Q/Q | - | Profit Margin | -505545.6% | RSI (14) | 59.09 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.81 | Sales Q/Q | - | SMA20 | 13.35% ($3.38) | Beta | 0.76 | Target Price | $15.56 |
| Payout | - | Debt/Eq | 1.13 | Earnings | 2026/9/28 | SMA50 | 0.76% ($3.8) | Rel Volume | 1.7 | Prev Close | $3.65 |
| Employees | 77 | LT Debt/Eq | 0.9 | EPS/Sales Surpr. | 32.68% -99.21% | SMA200 | -21.39% ($4.87) | Avg Volume(3M) | 1.91M | Price | $3.83 |
| IPO | 2020/7/10 | Option/Short | Yes/Yes | Trades | 10741 | Volume | 3,248,998 | Change | 4.93% |
🧬 Inventiva is a clinical-stage biotech company developing treatments for metabolic and fibrotic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, lanifibranor—an oral pan-PPAR (peroxisome proliferator-activated receptor) agonist that activates three receptor subtypes simultaneously—is being evaluated in a global Phase 3 clinical trial and features a differentiated mechanism of action that simultaneously targets anti-fibrosis, anti-inflammation, and metabolic improvement.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded more than usual. That is 170% of its average volume.
IVA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.7% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,526,255. Peers typically go for $1,231.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.6%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SURI Simplify Propel Opportunities ETF 0.02% 
MEDI Harbor Health Care ETF <0.01% 
LYTE Roundhill Photonics & Optics ETF <0.01% 
IEUS iShares MSCI Europe Small-Cap ETF <0.01% 
ISCF iShares International Small-Cap Equity Factor ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
BLCR iShares Large Cap Core Active ETF 9.6B 
CGMS Capital Group U.S. Multi-Sector Income 5.6B 
CGSD Capital Group Short Duration Income ETF 2.9B 
BFLX iShares Flexible Equity Active ETF 2.2B 
XHLF BondBloxx Bloomberg Six Month Target Duration US Treasury ETF 2.0B It ranks #161 of 597 in the industry
Based on market cap of $916M.
FAQ
What kind of company is IVA?
IVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IVA?
The market cap of IVA is approximately $916M, ranking 2,640 within its sector.
What is the 52-week high and low for IVA?
IVA has recorded a 52-week high of $7.29 and a low of $2.82.
